# A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

> **NCT05849298** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** AAA617
- **DRUG:** AAA517
- **DRUG:** Piflufolastat F 18
- **DRUG:** ARPI
- **DRUG:** ADT
- **OTHER:** Best supportive care

## Key facts

- **NCT ID:** NCT05849298
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-03
- **Primary completion:** 2026-12-23
- **Final completion:** 2026-12-23
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05849298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05849298, "A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05849298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*